07:53 AM EDT, 08/04/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) reported Q2 adjusted earnings Monday of $0.15 per diluted share, compared with $0.00 a year earlier.

Analysts surveyed by FactSet expected $0.01.

Revenue for the quarter ended June 30 was $163.4 million, compared with $ 109.3 million a year earlier.

Analysts surveyed by FactSet expected $149.8 million.

The biotech firm said it is maintaining its 2025 outlook of between $580 million and $600 million revenue for Orladeyo, an oral medication to treat hereditary angioedema in adults and children aged 12 and older.

Shares of BioCryst were up 5% in recent premarket activity.